Page 67 - Read Online

Dave et al. J Cancer Metastasis Treat 2020;6:46 I http://dx.doi.org/10.20517/2394-4722.2020.106 Page 29 of 36

44. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: an insight with iNOS
knockout mice. Am J Physiol Heart Circ Physiol 2002;282:H1996-2003.
45. Kaneider NC, Mosheimer B, Reinisch N, Patsch JR, Wiedermann CJ. Inhibition of thrombin-induced signaling by resveratrol and
quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res 2004;114:185-
94.
46. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-
regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-10.
47. Ge H, Zhang JF, Guo BS, He B, Wang BY, Wang CQ. Resveratrol inhibits expression of EMMPRIN from macrophages. Yao Xue Xue
Bao 2006;41:625-30.
48. Qin MZ, Gu QH, Tao J, Song XY, Gan GS, Luo ZB, Li BX. Ketamine effect on HMGB1 and TLR4 expression in rats with acute lung
injury. Int J Clin Exp Pathol 2015;8:12943-8.
49. Jones BA, Beamer M, Ahmed S. Fractalkine/CX3CL1: a potential new target for inflammatory diseases. Mol Interv 2010;10:263-70.
50. Lee B, Moon SK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular
smooth muscle cells. J Nutr 2005;135:2767-73.
51. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB
activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene
2004;23:9247-58.
52. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a
mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004;279:22727-37.
53. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated
human mammary epithelial cells. J Biol Chem 1998;273:21875-82.
54. Martín AR, Villegas I, Sánchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic
inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006;147:873-85.
55. Lin HY, Lansing L, Merillon JM, et al. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J 2006;20:1742-4.
56. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in
environmental toxicity and cancer. J Biol Chem 2004;279:23847-50.
57. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, et al. Resveratrol-induced apoptosis in MCF-7 human breast
cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005;115:74-84.
58. Casper RF, Quesne M, Rogers IM, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention
of dioxin toxicity. Mol Pharmacol 1999;56:784-90.
59. Hsieh TC, Wu JM. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell
lines. Exp Cell Res 1999;249:109-15.
60. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent
pathway. Carcinogenesis 1999;20:237-42.
61. Moreno JJ. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J Pharmacol Exp Ther
2000;294:333-8.
62. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett
1998;421:277-9.
63. Peng L, Jiang D. Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition. PLoS One 2018;13:e0205918.
64. Reto M, Figueira ME, Filipe HM, Almeida CM. Chemical composition of green tea (Camellia sinensis) infusions commercialized in
Portugal. Plant Foods Hum Nutr 2007;62:139-44.
65. Chung FL, Schwartz J, Herzog CR, Yang YM. Tea and cancer prevention: studies in animals and humans. J Nutr 2003;133:3268S-74.
66. McKay DL, Blumberg JB. The role of tea in human health: an update. J Am Coll Nutr 2002;21:1-13.
67. Sung H, Nah J, Chun S, Park H, Yang SE, Min WK. In vivo antioxidant effect of green tea. Eur J Clin Nutr 2000;54:527-9.
68. Ding S, Jiang J, Yu P, Zhang G, Liu X. Green tea polyphenol treatment attenuates atherosclerosis in high-fat diet-fed apolipoprotein
E-knockout mice via alleviating dyslipidemia and up-regulating autophagy. PLoS One 2017;12:e0181666.
69. Reygaert WC. Green tea catechins: their use in treating and preventing infectious diseases. Biomed Res Int 2018;2018:9105261.
70. Sang S, Lambert JD, Ho CT, Yang CS. The chemistry and biotransformation of tea constituents. Pharmacol Res 2011;64:87-99.
71. Gan RY, Li HB, Sui ZQ, Corke H. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG):
An updated review. Crit Rev Food Sci Nutr 2018;58:924-41.
72. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y. Influence of drinking green tea on breast cancer malignancy among
Japanese patients. Jpn J Cancer Res 1998;89:254-61.
73. Uehara M, Sugiura H, Sakurai K. A trial of oolong tea in the management of recalcitrant atopic dermatitis. Arch Dermatol 2001;137:42-3.
74. Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer 1998;31:151-9.
75. Rasheed A, Haider M. Antibacterial activity of Camellia sinensis extracts against dental caries. Arch Pharm Res 1998;21:348-52.
76. Guo YJ, Zhang B, Feng XS, Ren HX, Xu JR. Retraction Note: Human cathelicidin LL-37 enhance the antibiofilm effect of EGCG on
Streptococcus mutans. BMC Oral Health 2017;17:102.
77. Kaya Z, Yayla M, Cinar I, et al. Epigallocatechin-3-gallate (EGCG) exert therapeutic effect on acute inflammatory otitis media in rats. Int
J Pediatr Otorhinolaryngol 2019;124:106-10.
78. Zhu J, Jiang Y, Yang X, et al. Wnt/β-catenin pathway mediates (-)-Epigallocatechin-3-gallate (EGCG) inhibition of lung cancer stem